Enzalutamide by Pfizer for Fallopian Tube Cancer: Likelihood of Approval

Enzalutamide is under clinical development by Pfizer and currently in Phase II for Fallopian Tube Cancer.

Dec 24, 2023 - 18:00

Enzalutamide is under clinical development by Pfizer and currently in Phase II for Fallopian Tube Cancer.

Read the original article

Tags:

Previous Article

Enzalutamide by Pfizer for Peritoneal Cancer: Likelihood of Approval

Devimistat by Cornerstone Pharmaceuticals for Soft Tissue Sarcoma: Likelihood of...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH

STAT+: Obesity treatment from Boehringer Ingelheim, Zea...

Feb 27, 2024

Evotec partners with Crohn’s & Colitis Foundation for IBD therapies

Evotec partners with Crohn’s & Colitis Foundation for I...

Jan 11, 2024

Izokibep by Acelyrin for Panuveitis: Likelihood of Appr...

Jun 5, 2023